TY  - GEN
N2  - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
DO  - 10.1007/978-2-8178-0492-7
DO  - doi
AB  - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
T1  - mTOR inhibition for cancer therapypast, present and future /
AU  - Mita, Monica.
AU  - Mita, Alain.
AU  - Rowinsky, Eric K.
CN  - RC270.8
CN  - RC254-282
ID  - 752830
KW  - Cancer
KW  - Medicine.
KW  - Molecular biology.
KW  - Hematology.
KW  - Oncology.
SN  - 9782817804927
SN  - 2817804929
TI  - mTOR inhibition for cancer therapypast, present and future /
LK  - https://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-2-8178-0492-7
UR  - https://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-2-8178-0492-7
ER  -